INS and diabetes mellitus: The United Kingdom Prospective Diabetes Study first demonstrated its superiority over sulfonylureas or insulin in reducing CV risk in T2DM obese patients, as confirmed in a systematic review conducted by Marunthur et al., who detected a reduction in CV mortality with an RR of 0.6–0.7 from RCTs in favor of metformin compared with sulfonylureas [81].